ClinicalTrials.gg
Active, not recruitingNCT07160257Updated Jun 12, 2026

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of Maridebart cafraglutide and Placebo in Type 2 Diabetes Mellitus, sponsored by Amgen. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by Amgen — 3 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Amgen.

Enrollment
12th of 16
56 · median 221
Started
2025
with 2 others
Phase 1
5 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, this one is the 12th largest by enrollment, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 16 studies in Diabetes Mellitus, Type 2 by Amgen are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by Amgen, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the effect of maridebart cafraglutide relative to placebo on insulin sensitivity in participants with Type 2 Diabetes Mellitus (T2DM) treated with stable dose of metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • T2DM
  • Maridebart Cafraglutide
  • AMG 133
  • Insulin sensitivity
  • β-cell Function
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • before initiation of any study-specific activities/procedures.
  • Male or female participants aged ≥ 18 and ≤ 70 years at the time of signing informed consent.
  • ≥ 23.0 kg/m\^2 (Asian participants only) or ≥ 25 and ≤ 45 kg/m\^2 at screening.
  • Diagnosis of T2DM at least 6 months before screening based on the WHO classification.
  • Treatment of T2DM for at least 3 months prior to screening with diet and exercise and a stable dose of metformin (either immediate release or extended release), with or without a stable dose of 1 additional OAM other than metformin.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes mellitus (except T2DM or history of gestational diabetes).
  • History of proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy that requires acute treatment.
  • One or more episodes of severe hypoglycemia (Level 3 hypoglycemia as defined by the American Diabetes Association classification criteria) within 6 months before screening, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery.
  • Has modified diet or adopted any nutritional lifestyle modifications within 3 months prior to screening, as assessed by the investigator (or designee) based on participant self-report.
  • History of within the last 5 years before screening (except nonmelanoma skin cancers, cervical carcinoma in situ, or breast ductal carcinoma in situ).
  • Family (first-degree relative[s]) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2).
  • History or evidence of endocrine disorder (such as Cushing's syndrome) that can cause obesity.
  • History or evidence of disease that can directly or indirectly affect insulin production, insulin action, or glucose metabolism.
  • History of any of the following within 90 days before screening: myocardial infarction, unstable angina, coronary artery bypass graft surgery or other major cardiovascular surgery, percutaneous coronary intervention (diagnostic angiograms are permitted), , cerebrovascular accident, or decompensated congestive heart failure, or currently have Class III or IV heart failure.
  • History of chronic pancreatitis.
  • History of acute pancreatitis within 6 months before screening.
  • Positive test at screening.
  • Evidence of or C infection.
  • Estimated \< 60 mL/min/1.73 m\^2 calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation at screening.
  • value \< 12 g/dL (males) or \< 10 g/dL (females) at screening or check-in (Day -4).
  • Use within 90 days before randomization of medications, supplements, or alternative remedies for weight loss (eg, GLP-1RA, GIP agonists, phentermine/topiramate, naltrexone/bupropion, orlistat, and sympathomimetic drugs).
  • Use within 90 days before randomization of chronic (> 14 days) systemic therapy (excluding topical, intraocular, intranasal, intraarticular, or inhaled preparations).
  • Use within 90 days before randomization of medications that may cause significant weight gain including, but not limited to, atypical antipsychotic and mood stabilizers.
  • Current or prior use of herbal supplements that affect insulin or glucose within 30 days before randomization.
  • Currently receiving treatment in another device or drug study, or less than 30 days (or 5 half-lives, whichever is longer) since ending treatment on another investigational device or drug study(ies).
  • Participants of unwilling to adhere to requirements during treatment and for an additional 16 weeks after the last dose of IMP.
  • Participants who are breastfeeding or who plan to breastfeed while on study through 16 weeks after the last dose of IMP.
  • Participants planning to become pregnant while on study through 16 weeks after the last dose of IMP.
  • Major surgical procedure planned during the study.
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
  • History or evidence of any other disorder, condition, or disease (except for those outlined above) that, in the opinion of the investigator or medical monitor, if consulted as necessary, would pose a risk to participant's safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Maridebart cafraglutide

    Participants will receive maridebart cafraglutide subcutaneously (SC).

    Drug: Maridebart cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC.

    Drug: Placebo

Interventions

  • Maridebart cafraglutide will be administered SC.

    Also known as: AMG 133

  • DrugPlacebo

    Placebo will be administered SC.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25

    Time frame: Baseline and Week 25

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events

    Time frame: Up to Week 41

  2. Plasma Concentration of Maridebart Cafraglutide at Week 25

    Time frame: Week 25

  3. Number of Participants with Anti-maridebart Cafraglutide Antibody Formation

    Time frame: Up to Week 41

  4. Change from Baseline in Total Insulin Secretion at Week 25

    Measured as area under the curve (AUC) of insulin secretion rate (ISR) from hyperglycemic clamp (ISR0-120min).

    Time frame: Baseline and Week 25

  5. Change from Baseline in First Phase Incremental ISR from Hyperglycemic Clamp (ISR0-8min) at Week 25

    Time frame: Baseline and Week 25

  6. Change from Baseline in Second Phase Insulin Secretion at Week 25

    Measured as AUC of ISR from hyperglycemic clamp (ISR20-120min).

    Time frame: Baseline and Week 25

  7. Change from Baseline in Maximum Insulin Secretion at 8 Minutes at Week 25

    Measured as incremental ISR responses to arginine from hyperglycemic clamp at 8 minutes (ISRarg0-8min).

    Time frame: Baseline and Week 25

  8. Change from Baseline in Maximum Insulin Secretion at 30 Minutes at Week 25

    Measured as incremental ISR responses to arginine from hyperglycemic clamp at 30 minutes (ISRarg0-30min).

    Time frame: Baseline and Week 25

  9. Change from Baseline in ISR at Week 25

    Measured as total AUC (ISR0-240min) from standardized mixed meal tolerance test (sMMTT).

    Time frame: Baseline and Week 25

  10. Change from Baseline in Clamp Disposition Index (cDI) at Week 25

    Calculated as product of M-value and ISR0-120min from the hyperglycemic clamp.

    Time frame: Baseline and Week 25

  11. Change from Baseline in Post-meal Glucose Concentrations During sMMTT (Total and Incremental AUC0-240min) at Week 25

    Time frame: Baseline and Week 25

  12. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 25

    Time frame: Baseline and Week 25

  13. Change from Baseline in Fasting Glucose Concentration at Week 25

    Time frame: Baseline and Week 25

  14. Change from Baseline in Fasting Glucagon Concentration at Week 25

    Time frame: Baseline and Week 25

  15. Change from Baseline in Glucagon Concentration During sMMTT (Total and Incremental AUC0-240min) at Week 25

    Time frame: Baseline and Week 25

  16. Change from Baseline in Fasting Triglycerides at Week 25

    Time frame: Baseline and Week 25

  17. Change from Baseline in Fasting High-density Lipoprotein-cholesterol (HDL-C) at Week 25

    Time frame: Baseline and Week 25

  18. Change from Baseline in Fasting Non-HDL-C at Week 25

    Time frame: Baseline and Week 25

  19. Change from Baseline in Triglyceride Concentration During sMMTT (Total and Incremental AUC0-240min) at Week 25

    Time frame: Baseline and Week 25

  20. Change from Baseline in Fasting Free Fatty Acids (FFA) Concentration (During Hyperinsulinemic-euglycemic Clamp and sMMTT) at Week 25

    Time frame: Baseline and Week 25

  21. Change from Baseline in FFA Concentrations During sMMTT (Total AUC0-240min) at Week 25

    Time frame: Baseline and Week 25

  22. Change from Baseline in Percentage Body Fat at Week 25

    Time frame: Baseline and Week 25

  23. Change from Baseline in Body Fat Mass at Week 25

    Time frame: Baseline and Week 25

  24. Change from Baseline in Lean Body Mass at Week 25

    Time frame: Baseline and Week 25

  25. Change from Baseline in Body Weight at Week 25

    Time frame: Baseline and Week 25

  26. Change from Baseline in Waist Circumference at Week 25

    Time frame: Baseline and Week 25

  27. Change from Baseline in Hunger Fasting Appetite Visual Analog Scale (VAS) Score at Week 25

    Time frame: Baseline and Week 25

  28. Change from Baseline in Satiety Fasting Appetite VAS Score at Week 25

    Time frame: Baseline and Week 25

  29. Change from Baseline in Fullness Fasting Appetite VAS Score at Week 25

    Time frame: Baseline and Week 25

  30. Change from Baseline in Prospective Food Consumption Fasting Appetite VAS Score at Week 25

    Time frame: Baseline and Week 25

  31. Change from Baseline in Overall Fasting Appetite VAS Score at Week 25

    Time frame: Baseline and Week 25

  32. Change from Baseline in Hunger Appetite VAS Score During sMMTT at Week 25

    Time frame: Baseline and Week 25

  33. Change from Baseline in Satiety Appetite VAS Score During sMMTT at Week 25

    Time frame: Baseline and Week 25

  34. Change from Baseline in Fullness Appetite VAS Score During sMMTT at Week 25

    Time frame: Baseline and Week 25

  35. Change from Baseline in Prospective Food Consumption Appetite VAS Score During sMMTT at Week 25

    Time frame: Baseline and Week 25

  36. Change from Baseline in Overall Appetite VAS Score During sMMTT at Week 25

    Time frame: Baseline and Week 25

  37. Change from Baseline in Food Craving Inventory (FCI) Score at Week 25

    Time frame: Baseline and Week 25

  38. Change from Baseline in Caloric Intake During Ad Libitum Meal at Week 25

    Time frame: Baseline and Week 25

07

Study locations

1 site
  • ProSciento, Inc. - Main Clinic
    Chula Vista, California 91911-1350, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 15 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 8, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Nov 15, 2026
CompletionEst.
Mar 4, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160257
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 5, 2025
Primary completion
Nov 15, 2026 (estimated)
Completion
Mar 4, 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion